Every few years, a headline lands with a thud: acupuncture no better than placebo, large trial finds. Readers are invited to conclude that needling is an elaborate theater — that whatever benefit people feel is all in the mind.
But what if the "placebo" used in those trials was never quite a placebo to begin with? A review published in Zhongguo Zhen Jiu (Chinese Acupuncture & Moxibustion) in October 2026 makes a careful, evidence-backed case for exactly that doubt. It is not a clinical trial, and it proves nothing about whether acupuncture treats any condition. What it does is far more interesting: it asks whether our control groups are measuring what we think they are measuring.
The Quiet Problem in Acupuncture Research
To test whether a treatment works, researchers compare it against something that doesn't. For a pill, that's straightforward: a sugar pill that looks identical. For acupuncture, it is genuinely hard. How do you create a convincing "nothing" when the treatment is a needle going into skin?
The most common answer is shallow needling (浅刺 qiǎn cì) — inserting a needle only a millimeter or two into the skin, either at the same acupoint as the real treatment or at a nearby non-acupoint location. Participants usually can't tell the difference. The logic: if real acupuncture outperforms shallow needling, the difference must come from the specific technique, not from the ritual of being treated.
This logic rests on one assumption — that shallow needling is physiologically inert, a true "nothing." The new review, from a team at the China Academy of Chinese Medical Sciences (Luo et al., published October 12, 2026), argues that this assumption deserves scrutiny. Their reasoning centers on a humble immune cell: the mast cell.
Mast Cells: Where They Are and What They Do
Mast cells are best known for their role in allergies — they are the cells that release histamine when you encounter pollen. But they live in many tissues, including the skin, and they do far more than drive allergic reactions. When mechanically stimulated, they can degranulate: burst open and release a cocktail of bioactive substances — histamine, serotonin, substance P, cytokines — that activate local signaling pathways. Some of these pathways influence pain perception.
The review gathers the existing evidence on two things: where mast cells sit in the skin, and what happens when needles disturb them.
On location. Mast cells are densely distributed in the dermis and the subcutaneous tissue layer, particularly toward the body's periphery (the hands, feet, and limbs — precisely where most acupuncture is performed). Crucially, studies have found them in higher density in acupoint areas than in surrounding non-acupoint skin. Shallow needling — by design — targets exactly these two superficial layers. The "control" needle lands where the mast cells are thickest.
On mechanism. Needling can mechanically trigger local mast cell degranulation. The released substances then activate nearby signaling pathways, and in animal and mechanistic studies this cascade is associated with an analgesic (pain-dampening) effect. In other words, even a shallow prick may set off a real biological chain reaction.
If the Sham Is Active, the Math Changes
Consider what this implies for a standard trial. Researchers compare Group A (real acupuncture) against Group B (shallow needling) and measure the difference in pain relief. The headline conclusion — "acupuncture works" or "it's just placebo" — depends entirely on Group B being inactive.
But if shallow needling triggers mast cell degranulation and its own analgesic pathways, then the trial is not comparing treatment vs. nothing. It is comparing a stronger intervention vs. a weaker, mechanistically related one. A small difference between the groups would then be unsurprising — and it would not mean "the treatment does nothing." It would mean "the treatment does a bit more than something that already does something."
This is not a fringe objection. It is the same problem that has surfaced in other corners of acupuncture research: "sham" techniques that turn out to be physiologically active. The review's contribution is to connect the dots through one specific, testable biological mechanism — and to propose that future trials should distinguish between shallow needling at the same acupoint versus at a non-acupoint location, since mast cell density differs between the two.
A Guide to Reading the Next Headline
This paper is useful to you not as a verdict but as a lens. The next time you see "acupuncture no better than placebo," run through these questions — the same ones this review invites:
-
What exactly was the control? "Placebo" is a label, not a description. Was it shallow needling? A retractable fake needle that never breaks the skin? A non-acupoint insertion? Each carries different biological baggage.
-
Did the control beat doing nothing? If shallow needling outperforms a waitlist or usual-care group, then the trial measured two active interventions against each other — and the "placebo" label is misleading.
-
Was the trial asking the right question? A trial designed to isolate mechanism (what part of needling is "specific"?) is different from one designed to guide care (do patients feel better with this treatment?). A small specific effect can coexist with a large clinical benefit. Patients choose treatments by the second question.
Readers of this site's evidence reviews have seen this pattern before: the headline often says more about the trial's design assumptions than about the therapy itself.
What This Review Does — and Does Not — Show
Precision matters here, because this is exactly the kind of topic where both enthusiasts and skeptics overclaim. Let us be careful.
What it shows: There is a plausible, evidence-supported biological mechanism (mast cell distribution and degranulation) through which shallow-needling controls could produce analgesic effects. This gives researchers a concrete reason to rethink control design — and gives readers a concrete reason to read "sham-controlled" results with nuance.
What it does not show:
- It does not show that acupuncture works for any specific condition. This is a review of mechanisms and distribution, not a clinical outcome study. No patients, no pain scores, no efficacy claim.
- It does not prove that shallow needling always produces meaningful analgesia in practice. Mast cell degranulation is one step in a cascade; the magnitude of any clinical effect is still an open question.
- It does not mean every acupuncture trial to date is invalid. It means the interpretation of trials using shallow-needling controls needs adjusting — which is how science is supposed to work.
The Bigger Lesson
There is a quiet irony in this story. Acupuncture researchers invented shallow needling to satisfy the strictest standard of evidence — the randomized controlled trial — and in doing so may have built a control that quietly smuggles the treatment back in. The pursuit of rigor created its own blind spot.
The mast cell story won't be the last word on sham acupuncture. But it is a useful reminder of something this site returns to again and again: evidence doesn't interpret itself. The same data — a small gap between acupuncture and its control — can mean "it doesn't work" or "the control worked too." Telling the difference requires looking at how the evidence was made, not just at the headline number. That habit of looking under the hood is the most durable thing any study can teach you.
Source: Luo Z, Zhang Y, Ge X, et al. "Beyond the placebo effect: exploring the mast cell-dependent analgesic effect of shallow needling control." Zhongguo Zhen Jiu. 2026 Oct 12;46(10):1621-1626. DOI: 10.13703/j.0255-2930.20250704-k0005. PMID: 42864285.